MedKoo Cat#: 563158 | Name: VU-0155069
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VU-0155069 is a selective positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGlu₄). It enhances mGlu₄ receptor activity by binding to an allosteric site, thereby increasing the receptor's response to glutamate without directly activating it. This modulation of mGlu₄ is of interest in neurological disorders such as Parkinson’s disease, where mGlu₄ activation has been associated with neuroprotective and antiparkinsonian effects.

Chemical Structure

VU-0155069
VU-0155069
CAS#1130067-06-9

Theoretical Analysis

MedKoo Cat#: 563158

Name: VU-0155069

CAS#: 1130067-06-9

Chemical Formula: C26H27ClN4O2

Exact Mass: 462.1823

Molecular Weight: 462.97

Elemental Analysis: C, 67.45; H, 5.88; Cl, 7.66; N, 12.10; O, 6.91

Price and Availability

Size Price Availability Quantity
200mg USD 2,650.00 2 Weeks
500mg USD 3,650.00 2 Weeks
1g USD 4,450.00 2 Weeks
2g USD 7,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
VU-0155069; VU 0155069; VU0155069;
IUPAC/Chemical Name
N-[(1S)-2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-naphthalenecarboxamide
InChi Key
DRIMIUYGTDAQOX-KRWDZBQOSA-N
InChi Code
InChI=1S/C26H27ClN4O2/c1-17(28-25(32)20-7-6-18-4-2-3-5-19(18)14-20)16-30-12-10-22(11-13-30)31-24-9-8-21(27)15-23(24)29-26(31)33/h2-9,14-15,17,22H,10-13,16H2,1H3,(H,28,32)(H,29,33)/t17-/m0/s1
SMILES Code
O=C(C1=CC=C2C=CC=CC2=C1)N[C@@H](C)CN3CCC(N4C5=CC=C(Cl)C=C5NC4=O)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 462.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cheng M, Rizwan A, Jiang L, Bhujwalla ZM, Glunde K. Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer. Neoplasia. 2017 Aug;19(8):617-627. doi: 10.1016/j.neo.2017.05.004. Epub 2017 Jun 24. PubMed PMID: 28654865; PubMed Central PMCID: PMC5487306. 2: Hur JH, Park SY, Dall'Armi C, Lee JS, Di Paolo G, Lee HY, Yoon MS, Min DS, Choi CS. Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect. Sci Rep. 2016 Dec 15;6:39170. doi: 10.1038/srep39170. PubMed PMID: 27976696; PubMed Central PMCID: PMC5156943. 3: Song HI, Yoon MS. PLD1 regulates adipogenic differentiation through mTOR - IRS-1 phosphorylation at serine 636/639. Sci Rep. 2016 Nov 22;6:36968. doi: 10.1038/srep36968. PubMed PMID: 27872488; PubMed Central PMCID: PMC5181839. 4: Tsai YR, Huang LJ, Lin HY, Hung YJ, Lee MR, Kuo SC, Hsu MF, Wang JP. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):507-19. doi: 10.1007/s00210-013-0851-6. Epub 2013 Mar 23. PubMed PMID: 23525454.